What question did this study set out to answer?

The study aims to evaluate the safety and antitumor activity of temsirolimus in combination with letrozole in postmenopausal women with metastatic breast cancer.

June 1, 2005Journal of Clinical Oncology

Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer

View Full Paper

Ask AI

Bookmark

Authors

JCJ. CarpenterHouston Methodist HRH. RochéThe University of Texas MD Anderson Cancer Center MCMario CamponeUniversité Claude Bernard Lyon 1

Discussion

Member takes

Implication

Randomized trial evaluates safety and effectiveness of temsirolimus combined with letrozole in postmenopausal women with metastatic breast cancer, indicating potential benefits.

Key Points

The study aims to evaluate the safety and antitumor activity of temsirolimus in combination with letrozole in postmenopausal women with metastatic breast cancer.
Randomized trial with 92 patients divided into three arms: letrozole alone, letrozole with tem daily, and letrozole with tem intermittent.
Patients received 2.5 mg letrozole daily, with tem adjusted to 10 mg daily or 30 mg intermittent due to dose-related issues.
Evaluated toxicities and progression-free survival (PFS) outcomes.
Clinical benefit (CR + PR + SD ≥8 weeks) was reported at 82% for tem daily, 83% for tem intermittent, and 79% for letrozole alone.
Progression-free survival at 1 year was estimated at 69% for tem daily, 62% for tem intermittent, and 48% for letrozole alone.
Median PFS was 9.2 months for the letrozole alone arm, with ongoing evaluations for combination groups.

Cite This Study

Carpenter et al. (2005) studied this question.

synapsesocial.com/papers/6a1d3d871c2cbcb15c5dfeb2 https://doi.org/10.1200/jco.2005.23.16_suppl.564

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial evaluates safety and effectiveness of temsirolimus combined with letrozole in postmenopausal women with metastatic breast cancer, indicating potential benefits.

Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider